These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20194855)

  • 21. Update on lymphadenectomy in early and advanced ovarian cancer.
    Angioli R; Plotti F; Palaia I; Calcagno M; Montera R; Cafà EV; Sereni MI; Panici PB
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):34-9. PubMed ID: 18197003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Hoppenau B; du Bois A;
    Gynecol Oncol; 2006 Feb; 100(2):300-7. PubMed ID: 16199079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
    Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
    Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
    J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of retroperitoneal lymphadenectomy on prognosis of patients with epithelial ovarian cancer.
    Wang Z; Xiong Z; Wang S
    Chin Med J (Engl); 2003 Apr; 116(4):588-92. PubMed ID: 12875728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The surgical treatment of ovarian cancer].
    Burghardt E; Lahousen M; Stettner H
    Geburtshilfe Frauenheilkd; 1990 Sep; 50(9):670-7. PubMed ID: 2272432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study.
    Fagotti A; De Iaco P; Fanfani F; Vizzielli G; Perelli F; Pozzati F; Perrone AM; Turco LC; Scambia G
    Ann Surg Oncol; 2012 Oct; 19(11):3522-7. PubMed ID: 22644507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.
    Mahner S; Eulenburg C; Staehle A; Wegscheider K; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J; du Bois A
    Eur J Cancer; 2013 Jan; 49(1):142-9. PubMed ID: 22921185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lymphadenectomy in the treatment of malignant ovarian germ cell tumor].
    Jin Y; Pan LY; Huang HF; Shen K; Wu M; Yang JX; Lang JH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Dec; 27(6):743-8. PubMed ID: 16447650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.
    Munkarah AR; Hallum AV; Morris M; Burke TW; Levenback C; Atkinson EN; Wharton JT; Gershenson DM
    Gynecol Oncol; 1997 Jan; 64(1):13-7. PubMed ID: 8995541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
    J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of lymphadenectomy and survival in stage I ovarian cancer patients.
    Chan JK; Munro EG; Cheung MK; Husain A; Teng NN; Berek JS; Osann K
    Obstet Gynecol; 2007 Jan; 109(1):12-9. PubMed ID: 17197582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.